Introduction to SGLT2 Inhibitors

Sodium–glucose cotransporter 2 (SGLT2) inhibitors represent a well-established class of oral antihyperglycemic agents used in the management of type 2 diabetes mellitus (T2DM). Unlike many other diabetes drugs that rely on stimulating insulin secretion or improving insulin sensitivity, SGLT2 inhibitors work by directly modifying renal glucose handling. By blocking the reabsorption of glucose in the proximal tubule of the nephron, these agents reduce plasma glucose concentrations in an insulin-independent manner. This unique mechanism also confers additional metabolic and hemodynamic benefits that extend beyond glycemic control, including reductions in body weight, blood pressure, and, most notably, improved cardiovascular and renal outcomes. This article provides a detailed examination of the mechanism of action of SGLT2 inhibitors, their physiological impact, clinical benefits, side effects, and considerations for clinical practice.

Renal Physiology of Glucose Handling

To appreciate how SGLT2 inhibitors function, one must first understand the kidney’s role in glucose homeostasis. Under normal physiological conditions, the kidneys filter approximately 180 grams of glucose per day in a healthy adult. This filtered load is nearly completely reabsorbed along the proximal tubule, with less than 0.5 grams appearing in the urine. The reabsorption process is mediated by two major sodium–glucose cotransporters: SGLT2 and SGLT1.

SGLT2 is a high-capacity, low-affinity transporter expressed predominantly in the early segment (S1 and S2 segments) of the proximal convoluted tubule. It accounts for roughly 90% of glucose reabsorption. SGLT1, a high-affinity, low-capacity transporter, is located in the more distal S3 segment of the proximal tubule and reabsorbs the remaining 10%. Both transporters couple the transport of glucose with the inward movement of sodium ions, utilizing the electrochemical gradient generated by the basolateral Na⁺/K⁺-ATPase pump.

Under normal fasting conditions, plasma glucose concentration is maintained around 5–6 mM (~90–110 mg/dL). After a meal, glucose levels rise and the filtered load increases proportionally. When the filtered glucose exceeds the transport maximum (TmG) of the proximal tubule — approximately 375 mg/min in a typical adult — glucose spills into the urine (glucosuria). This threshold is usually reached at plasma glucose levels around 180–200 mg/dL (10–11 mM). In individuals with diabetes, the elevated plasma glucose overwhelms the reabsorptive capacity, leading to significant glucosuria. However, even in diabetes, the kidneys attempt to retain glucose by upregulating SGLT2 expression, paradoxically worsening hyperglycemia.

Mechanism of Action of SGLT2 Inhibitors

SGLT2 inhibitors are competitive antagonists of the SGLT2 protein. By binding to the transporter’s glucose- or sodium-binding sites, they prevent the cotransport of sodium and glucose from the tubular lumen into the proximal tubule epithelial cells. This blockade reduces glucose reabsorption by 30–50%, causing a substantial amount of filtered glucose to remain in the tubular fluid and be excreted in the urine. The reduction in reabsorption is not total because SGLT1 can partially compensate, especially when SGLT2 is fully inhibited.

The effect is dose-dependent and saturable. At therapeutic doses, SGLT2 inhibitors produce a modest lowering of plasma glucose by facilitating urinary glucose excretion of 60–80 grams per day. This corresponds to an energy loss of 240–320 kcal/day, which contributes to weight loss. Importantly, the action of SGLT2 inhibitors does not depend on the presence of endogenous insulin or β-cell function; therefore, they are effective across a wide range of disease stages, including in patients with severe insulin resistance or relative insulin deficiency.

Kinetics and Selectivity

Clinically available SGLT2 inhibitors — such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin — differ in their selectivity for SGLT2 versus SGLT1. Empagliflozin and dapagliflozin are highly selective for SGLT2 (>200-fold selectivity over SGLT1), while canagliflozin is less selective (~250-fold selectivity) but still primarily inhibits SGLT2 at therapeutic doses. The selectivity influences the degree of gastrointestinal SGLT1 blockade, which may affect postprandial glucose absorption. Nonetheless, the primary glucose-lowering effect is renal.

The pharmacokinetic profiles of these drugs allow once-daily oral dosing, with rapid absorption and long half-lives that sustain inhibition throughout the day. All are predominantly excreted unchanged in the urine, with minimal hepatic metabolism. Dosing adjustments are required for patients with moderate renal impairment, and use is generally not recommended when the estimated glomerular filtration rate (eGFR) falls below 25–30 mL/min/1.73 m² due to reduced efficacy.

Physiological Consequences of SGLT2 Inhibition

The immediate consequence of SGLT2 blockade is increased urinary glucose excretion (UGE). This leads to a reduction in plasma glucose concentrations that is accompanied by several secondary physiological changes.

Hemodynamic and Diuretic Effects

Because SGLT2 transports sodium along with glucose, its inhibition also promotes natriuresis — the excretion of sodium in the urine. This osmotic diuresis results in a modest reduction in plasma volume, which lowers systolic and diastolic blood pressure by 3–5 mmHg. The reduction in blood pressure is independent of glycemic improvement and is maintained during long-term therapy. The diuretic effect also contributes to a temporary increase in urine output, which can lead to symptoms of thirst and, in susceptible individuals, dehydration or electrolyte disturbances.

Weight Loss and Energy Balance

The caloric loss from glucose excretion produces a negative energy balance. On average, patients lose 2–4 kg over the first 6–12 months of treatment, with subsequent weight stabilization. This weight loss is modest compared to lifestyle interventions but clinically meaningful, especially when combined with other cardiovascular risk reduction strategies. The loss of glucose-derived calories also leads to a compensatory increase in appetite in some patients, which may attenuate weight reduction over time. However, the net effect remains positive for most individuals.

Impact on Renal Function

SGLT2 inhibitors have a well-documented renoprotective effect that extends beyond glucose lowering. By reducing intraglomerular pressure through afferent arteriole constriction (mediated by tubuloglomerular feedback), these drugs lower the intraglomerular hyperfiltration commonly observed in early diabetic kidney disease. This reduction in hyperfiltration slows the progression of albuminuria and preserves eGFR over the long term. Large outcome trials such as the CREDENCE trial and DAPA-CKD trial have demonstrated that SGLT2 inhibitors reduce the risk of progression to end-stage kidney disease, renal death, and cardiovascular mortality in patients with chronic kidney disease, with or without diabetes.

Clinical Benefits of SGLT2 Inhibitors

The therapeutic advantages of SGLT2 inhibitors extend well beyond glucose lowering. They have become cornerstones in the management of T2DM, especially in patients with established cardiovascular disease, heart failure, or chronic kidney disease.

Glycemic Control

By the primary mechanism described, SGLT2 inhibitors lower HbA1c by approximately 0.5–1.0% (depending on baseline renal function and medication adherence). Their efficacy is greater in patients with higher starting glycemic levels and lower in those with advanced renal impairment. Because SGLT2 inhibitors do not stimulate insulin secretion, the risk of hypoglycemia is low when used as monotherapy or in combination with agents that do not cause hypoglycemia. However, when combined with sulfonylureas or insulin, close monitoring is needed.

Cardiovascular Protection

Perhaps the most celebrated benefit of SGLT2 inhibitors is their reduction of major adverse cardiovascular events (MACE) and heart failure hospitalizations. The landmark EMPA-REG OUTCOME trial first demonstrated that empagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% in patients with T2DM and established cardiovascular disease. Subsequent trials — CANVAS, DECLARE-TIMI 58, and VERTIS — confirmed similar benefits across the class. The reduction in heart failure hospitalizations is particularly robust, with an approximately 30–35% relative risk reduction observed consistently. These cardiovascular benefits are believed to arise from a combination of hemodynamic, metabolic, and direct myocardial effects, including improved cardiac energetics, reduced myocardial fibrosis, and enhanced ventricular function.

Renal Protection

As noted, the renoprotective effects of SGLT2 inhibitors have been validated in dedicated kidney outcome trials. The reduction in albuminuria, stabilization of eGFR, and lower risk of progression to kidney failure make these drugs essential tools in nephrology. For patients with type 2 diabetes and chronic kidney disease, current guidelines recommend SGLT2 inhibitors as a first-line therapy alongside metformin and ACE inhibitors/ARBs.

Side Effects and Clinical Considerations

While SGLT2 inhibitors have a favorable risk-benefit profile, they are not without adverse effects. The most common side effects are related to the increased concentration of glucose in the urine.

Genitourinary Infections

Glucosuria increases the risk of urinary tract infections and genital mycotic infections (e.g., balanitis, vulvovaginitis). Genital infections occur in about 5–8% of patients, more frequently in women and uncircumcised men. Most are mild and manageable with standard antifungal therapy. Serious urinary tract infections, including pyelonephritis, are rarer but can be severe.

Volume Depletion and Hypotension

The diuretic effect can produce a drop in blood pressure, especially in elderly patients or those on loop or thiazide diuretics, and in individuals with impaired renal function. Symptoms include dizziness, orthostatic hypotension, and, rarely, syncope. Monitoring volume status and adjusting concomitant medications is critical in the first few weeks of therapy.

Diabetic Ketoacidosis (DKA)

A rare but serious complication is euglycemic DKA (ketoacidosis with blood glucose <250 mg/dL), particularly in patients with type 1 diabetes or those with severe illness, surgery, or very low carbohydrate intake. The mechanism is thought to involve increased glucagon secretion, enhanced ketogenesis, and impaired ketone clearance. Patients should be educated about symptoms of DKA and advised to stop the drug during acute illness or prolonged fasting.

Acute Kidney Injury

Although SGLT2 inhibitors are generally protective of kidney function, acute kidney injury (AKI) has been reported, especially in patients with pre-existing volume depletion, concurrent nephrotoxic medications, or sepsis. Evaluation of renal function before initiating therapy and periodic monitoring thereafter is recommended.

Lower Limb Amputations and Bone Fractures

Observational data and the CANVAS trial reported an increased risk of non-traumatic lower limb amputations (primarily toes) with canagliflozin. The risk appears to be drug-specific and is not seen with empagliflozin or dapagliflozin. Additionally, some studies suggested a possible increase in bone fractures due to falls related to volume depletion or direct effects on bone metabolism, although the evidence is inconsistent. Careful patient selection and education are important.

Contraindications and Patient Selection

SGLT2 inhibitors are contraindicated in patients with type 1 diabetes (except under specific protocols), history of severe hepatic impairment, and prior serious allergic reactions. They should not be used in patients with eGFR below 25–30 mL/min/1.73 m² for glycemic control, though they may still be indicated for renoprotection in some cases (e.g., dapagliflozin in CKD). Pregnant or breastfeeding women should not take these agents. Careful assessment of volume status and concomitant medications is essential before prescribing.

Current Guidelines and Place in Therapy

In 2025, SGLT2 inhibitors are recommended as a foundational therapy for patients with T2DM who have established atherosclerotic cardiovascular disease, heart failure (with reduced or preserved ejection fraction), or chronic kidney disease. They are often used in combination with metformin, GLP-1 receptor agonists, or insulin, depending on patient needs. Their cardiovascular and renal benefits have, in many guidelines, elevated them to first-line status alongside metformin for appropriate patients. For more detailed recommendations, please consult the American Diabetes Association Standards of Care and the KDIGO guidelines on diabetes and CKD.

Conclusion

SGLT2 inhibitors have transformed the treatment landscape for type 2 diabetes and beyond. Their unique mechanism — blocking glucose reabsorption in the kidney — provides effective glycemic control independent of insulin, while also delivering significant weight loss, blood pressure reduction, and, most importantly, cardiovascular and renal protection. Understanding the molecular and physiological basis of these agents enables healthcare professionals to make informed prescribing decisions, optimize patient outcomes, and mitigate risks. Careful patient selection, education about side effects, and monitoring remain essential components of safe and effective use.